Patents by Inventor Beilei Wang

Beilei Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200323850
    Abstract: The present invention relates to a kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising the kinase inhibitor, and to uses and methods for using these compounds and compositions to inhibit the activity of wild-type FLT3, mutant FLT3-ITD, PDGFR? and/or PDGFR? kinase in a cell or a subject, as well as uses and methods of these compounds and compositions to preventing or treating kinase-associated conditions in a subject.
    Type: Application
    Filed: December 26, 2017
    Publication date: October 15, 2020
    Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Qingsong LIU, Jing LIU, Xiaofei LIANG, Beilei WANG, Kailin YU, Zongru JIANG, Cheng CHEN, Chen HU, Wenchao WANG, Fengming ZOU, Qingwang LIU, Feng LI, Wenliang WANG, Li WANG
  • Patent number: 10793543
    Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: October 6, 2020
    Assignees: PRECEDO PHARMACEUTICALS CO., LTD, HEFEI GRACEVO BIO-MEDICINE CO., LTD
    Inventors: Qingsong Liu, Jing Liu, Qiang Wang, Beilei Wang, Feiyang Liu, Shuang Qi, Ziping Qi, Fengming Zou, Cheng Chen, Wenchao Wang, Chen Hu, Xiaochuan Liu, Wei Wang, Aoli Wang, Li Wang, Zhenquan Hu, Tao Ren
  • Patent number: 10781282
    Abstract: A reaction system, such as for forming a rigid polyurethane foam, includes a flame retardant polyol that is a brominated reaction product of a cardanol component, a bromine component, and an additive component. The cardanol component includes at least 80 wt % of cardanol, based on the total weight of the cardanol component, and the bromine component including at least 80 wt % of bromine, based on the total weight of the bromine component.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: September 22, 2020
    Assignee: Dow Global Technologies LLC
    Inventors: Beilei Wang, Yi Zhang, Hongyu Chen, Renhua Fan, Min Yang
  • Patent number: 10781214
    Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: September 22, 2020
    Assignee: PRECEDO PHARMACEUTICALS CO., LTD.
    Inventors: Qingsong Liu, Jing Liu, Xixiang Li, Aoli Wang, Hong Wu, Kailin Yu, Chen Hu, Wenchao Wang, Cheng Chen, Fengming Zou, Ziping Qi, Li Wang, Beilei Wang
  • Publication number: 20200270452
    Abstract: A polyurethane based filament winding resin reaction mixture, a resin bath and a filament winding apparatus are set forth. The reaction mixture comprises an isocyanate component including one or more isocyanates and an isocyanate-reactive component including from 5 wt % to 95 wt % of one of more polyols having a number acerage molecular weight from 50 g/mol to 8,000 g/mol, from 2 wt % to 30 wt % of one or more propane based triols, and from 1 wt % to 15 wt % of one or more trimester-phosphates, based on the total weight of the isocyanate-reactive component. A ratio of a total weight of the one or more propane based triols to a total weight of the one or more trimester-phosphates is between 1.1 and 5.0.
    Type: Application
    Filed: December 15, 2015
    Publication date: August 27, 2020
    Inventors: Beilei WANG, Jiang LI, Paolo DIENA
  • Patent number: 10669238
    Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 2, 2020
    Assignee: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Jing Liu, Qingsong Liu, Qianmao Liang, Yongfei Chen, Cheng Chen, Aoli Wang, Hong Wu, Kailin Yu, Wei Wang, Chen Hu, Wenchao Wang, Shuang Qi, Beilei Wang, Li Wang
  • Publication number: 20200010471
    Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).
    Type: Application
    Filed: June 5, 2017
    Publication date: January 9, 2020
    Applicant: PRECEDO PHARMACEUTICALS CO., LTD
    Inventors: Qingsong LIU, Jing LIU, Xixiang LI, Aoli WANG, Ziping QI, Hong WU, Jiaxin WU, Wenchao WANG, Chen HU, Cheng CHEN, Li WANG, Beilei WANG
  • Publication number: 20190333682
    Abstract: A transformer, a method for manufacturing the same and an electromagnetic device are disclosed. The transformer includes a base plate, a magnetic core, input line layers, coupling line layers and conductive parts. The base plate includes a central part defining multiple inner via holes and a peripheral part defining multiple outer via holes. The magnetic core is embedded in an annular accommodating groove formed between the central part and the peripheral part. The input line layers are disposed on two sides of the base plate. Input lines of the input line layers are connected in order by corresponding conductive parts to form an input coil circuit. The coupling line layers are disposed on two opposite sides of the base plate. Coupling lines of the coupling line layers are connected in order by corresponding conductive parts to form a coupling coil circuit.
    Type: Application
    Filed: June 18, 2019
    Publication date: October 31, 2019
    Inventors: WEIJING GUO, BEILEI WANG, YUHUA ZENG, HUA MIAO
  • Publication number: 20190333681
    Abstract: An electromagnetic device and a method for manufacturing the same are disclosed. The electromagnetic device includes a base plate, a magnetic core, multiple transmission units, and connection layers. The base plate includes a central part defining multiple inner via holes and a peripheral part defining multiple outer via holes. An annular accommodating groove is defined between the central part and the peripheral part. The magnetic core is received in the annular accommodating groove. Transmission units are located on both sides of the base plate. Each transmission unit includes a transmission wire layer including multiple conductive wire patterns, and each conductive wire pattern bridges one inner via hole and one outer via hole. Each of the connection layers is set on one side of the transmission wire layer close to the base plate. At least one connection layer has a dielectric loss no larger than 0.02.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 31, 2019
    Inventors: BEILEI WANG, WEIJING GUO, YUHUA ZENG, HUA MIAO, ZHANHAO XIE
  • Patent number: 10457770
    Abstract: A surfactant and a method of forming the surfactant having the formula (I) where a is an integer from 1 to 10, b is an integer from 0 to 10, R1 is —CH3 or —H, n is an integer from 0 to 20, and R2 is a moiety selected from the group consisting of (II), (III), (IV), (V), (VI), (VII) or (VIII) where m is an integer from 0 to 4. The surfactant can be used in a method for preparing a rigid polyurethane foam.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: October 29, 2019
    Assignee: Dow Global Technologies, LLC
    Inventors: Jiawen Xiong, Dachao Li, Jianxin Zhang, David Hong-fei Guo, Beilei Wang, Wei Liu
  • Patent number: 10350210
    Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: July 16, 2019
    Assignee: PRECEDO PHARMACEUTICALS CO., LTD
    Inventors: Jing Liu, Qingsong Liu, Taoshan Jiang, Aoli Wang, Jiaxin Wu, Hong Wu, Ziping Qi, Yongfei Chen, Fengming Zou, Wenchao Wang, Zheng Zhao, Li Wang, Beilei Wang
  • Patent number: 10266535
    Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: April 23, 2019
    Assignees: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, HEFEI COSOURCE PHARMACEUTICAL CO., LTD.
    Inventors: Jing Liu, Qingsong Liu, Xixiang Li, Aoli Wang, Hong Wu, Cheng Chen, Wenchao Wang, Chen Hu, Zheng Zhao, Jiaxin Wu, Juan Liu, Kailin Yu, Wei Wang, Li Wang, Beilei Wang
  • Publication number: 20190084960
    Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.
    Type: Application
    Filed: March 28, 2017
    Publication date: March 21, 2019
    Applicants: PRECEDO PHARMACEUTICALS CO., LTD, HEFEI GRACEVO BIO-MEDICINE CO., LTD
    Inventors: Qingsong LIU, Jing LIU, Qiang WANG, Beilei WANG, Feiyang LIU, Shuang QI, Ziping QI, Fengming ZOU, Cheng CHEN, Wenchao WANG, Chen HU, Xiaochuan LIU, Wei WANG, Aoli WANG, Li WANG, Zhenquan HU, Tao REN
  • Publication number: 20190040013
    Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.
    Type: Application
    Filed: December 22, 2016
    Publication date: February 7, 2019
    Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Jing LIU, Qingsong LIU, Qianmao LIANG, Yongfei CHEN, Cheng CHEN, Aoli WANG, Hong WU, Kailin YU, Wei WANG, Chen HU, Wenchao WANG, Shuang QI, Beilei WANG, Li WANG
  • Publication number: 20190010159
    Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.
    Type: Application
    Filed: December 27, 2016
    Publication date: January 10, 2019
    Applicant: PRECEDO PHARMACEUTICALS CO., LTD
    Inventors: Qingsong LIU, Jing LIU, Xixiang LI, Aoli WANG, Hong WU, Kailin YU, Chen HU, Wenchao WANG, Cheng CHEN, Fengming ZOU, Ziping QI, Li WANG, Beilei WANG
  • Publication number: 20180369242
    Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.
    Type: Application
    Filed: December 15, 2016
    Publication date: December 27, 2018
    Applicant: PRECEDO PHARMACEUTICALS CO., LTD
    Inventors: Jing LIU, Qingsong LIU, Taoshan JIANG, Aoli WANG, Jiaxin WU, Hong WU, Ziping QI, Yongfei CHEN, Fengming ZOU, Wenchao WANG, Zheng ZHAO, Li WANG, Beilei WANG
  • Patent number: 10144845
    Abstract: A cardanol modified epoxy polyol may be used for forming a polyurethane resin system for use in applications such as coatings and composites formed by filament winding. The polyurethane resin system includes an isocyanate-reactive component that has a first cardanol component and the cardanol-modified epoxy polyol, and includes an isocyanate component that includes at least one polyisocyanate. The cardanol-modified epoxy polyol is a reaction product of an epoxy component and an epoxy-reactive component at a ratio of epoxy groups to epoxy reactive groups from 1:0.95 to 1:5, and the epoxy-reactive component includes a second cardanol component.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: December 4, 2018
    Assignee: Dow Global Technologies LLc
    Inventors: Jiang Li, Yi Zhang, Wei Li, Beilei Wang, Paolo Diena
  • Publication number: 20180030054
    Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).
    Type: Application
    Filed: August 7, 2015
    Publication date: February 1, 2018
    Applicants: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, HEFEI COSOURCE PHARMACEUTICAL CO., LTD.
    Inventors: Jing LIU, Qingsong LIU, Xixiang LI, Aoli WANG, Hong WU, Cheng CHEN, Wenchao WANG, Chen HU, Zheng ZHAO, Jiaxin WU, Juan LIU, Kailin YU, Wei WANG, Li WANG, Beilei WANG
  • Patent number: 9814709
    Abstract: The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: November 14, 2017
    Assignees: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD.
    Inventors: Qingsong Liu, Jing Liu, Yongfei Chen, Hong Wu, Aoli Wang, Beilei Wang, Chen Hu, Wenchao Wang, Cheng Chen
  • Publication number: 20170320999
    Abstract: A surfactant and a method of forming the surfactant having the formula (I) where a is an integer from 1 to 10, b is an integer from 0 to 10, R1 is —CH3 or —H, n is an integer from 0 to 20, and R2 is a moiety selected from the group consisting of (II), (III), (IV), (V), (VI), (VII) or (VIII) where m is an integer from 0 to 4. The surfactant can be used in a method for preparing a rigid polyurethane foam.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 9, 2017
    Applicant: Dow Global Technologies LLC
    Inventors: Jiawen Xiong, Dachao Li, Jianxin Zhang, David Hong-fei Guo, Beilei Wang, Wei Liu